Demographics and clinical characteristics of newly diagnosed AML patients in the study
| . | . | All cases . | Treated cases . |
|---|---|---|---|
| N | 511 | 415 | |
| Male:Female | 291:220 | 218:197 | |
| Age, y | Min | 15.8 | 15.8 |
| Max | 87.23 | 87.4 | |
| Median | 65.7 | 64.3 | |
| Cyto, % | Favorable | 6.7 | 8.0 |
| Intermediate | 44.0 | 47.0 | |
| Unfavorable | 49.3 | 45.1 | |
| FLT3, % | ITD | 14.9 | 17.8 |
| D835 | 3.1 | 5.8 | |
| Both | 1.6 | 1.9 | |
| Zubrod PS, % | 3 or 4 | 3.3 | 3.1 |
| AHD, % | ≥ 2 | 39.9 | 37.1 |
| Infection, % | Yes | 19.8 | 22.2 |
| WBC | Median | 8.8 | 9.9 |
| Platelet | Median | 56 | 55.5 |
| Hemoglobin | Median | 9.6 | 9.6 |
| BM blast, % | Median | 46 | 50 |
| PB blast, % | Median | 18 | 20.5 |
| Response, % | CR | 57.1 | |
| Resistant | 32.8 | ||
| Fail | 10.1 | ||
| Relapse | 61.6% | ||
| Alive | 25.8% | ||
| Median overall survival, wk | 49.14 | ||
| Median remission duration, wk | 45.86 |
| . | . | All cases . | Treated cases . |
|---|---|---|---|
| N | 511 | 415 | |
| Male:Female | 291:220 | 218:197 | |
| Age, y | Min | 15.8 | 15.8 |
| Max | 87.23 | 87.4 | |
| Median | 65.7 | 64.3 | |
| Cyto, % | Favorable | 6.7 | 8.0 |
| Intermediate | 44.0 | 47.0 | |
| Unfavorable | 49.3 | 45.1 | |
| FLT3, % | ITD | 14.9 | 17.8 |
| D835 | 3.1 | 5.8 | |
| Both | 1.6 | 1.9 | |
| Zubrod PS, % | 3 or 4 | 3.3 | 3.1 |
| AHD, % | ≥ 2 | 39.9 | 37.1 |
| Infection, % | Yes | 19.8 | 22.2 |
| WBC | Median | 8.8 | 9.9 |
| Platelet | Median | 56 | 55.5 |
| Hemoglobin | Median | 9.6 | 9.6 |
| BM blast, % | Median | 46 | 50 |
| PB blast, % | Median | 18 | 20.5 |
| Response, % | CR | 57.1 | |
| Resistant | 32.8 | ||
| Fail | 10.1 | ||
| Relapse | 61.6% | ||
| Alive | 25.8% | ||
| Median overall survival, wk | 49.14 | ||
| Median remission duration, wk | 45.86 |
AML indicates acute myeloid leukemia; Cyto, cytogenetic; FLT3, FMS-like tyrosine kinase 3; PS, performance status; AHD, antecedent hematologic disorder; WBC, white blood cell; and PB, peripheral blood.